… Concomitant capecitabine 1,650 mg/m 2 /d was administered with or without cetuximab 250
mg/m 2 weekly during the radiotherapy. Dose adjustment was … David Gonzalez de Castro …

The progressive elucidation of the molecular pathogenesis of cancer has fueled the rational
development of targeted drugs for patient populations stratified by genetic characteristics. …

… David Gonzalez de Castro, David Gonzalez de Castro … Oscier, Matthew JJ Rose-Zerilli,
Nils Winkelmann, David Gonzalez de Castro, Belen Gomez, Jade Forster, Helen Parker, Anton …

Children with Down syndrome (DS) have a greatly increased risk of acute megakaryoblastic
leukemia (AMKL) and acute lymphoblastic leukemia (ALL). Both DS-AMKL and the related …

Tumor genomic instability and selective treatment pressures result in clonal disease evolution;
molecular stratification for molecularly targeted drug administration requires repeated …

… David Gonzalez de Castro; David Gonzalez de Castro … Aliki Xochelli, Achilles Anagnostopoulos,
Claudia Fazi, David Gonzalez de Castro, Claire Dearden, Guy Pratt, Richard Rosenquist…

… David Gonzalez de Castro, David Gonzalez de Castro … A highly significant treatment
interaction for OS was seen (chi-square test = 16; P < .001; HR = 6.4; 95% CI = 2.3-17.8; Figure 1D), …

… David Gonzalez De Castro; David Gonzalez De Castro … D, Mutation concordance between
primary and advanced tumor samples for 34 patients with targetable mutations in NF1, AKT1, …

Acquired resistance to selective FLT3 inhibitors is an emerging clinical problem in the treatment
of FLT3-ITD+ acute myeloid leukaemia (AML). The paucity of valid pre-clinical models …

Background: KRAS mutation testing is required to select patients with metastatic colorectal
cancer (CRC) to receive anti-epidermal growth factor receptor antibodies, but the optimal …